Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

Journal Articles

Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation

Wei Li, Ruiui Wang, Junhao Wang, Dafei Chai, Xiaohui Xie, Ken H. H. Young, Ya Cao, Yong Li, Xinfang Yu

Blood blood.2024026781.

https://doi.org/10.1182/blood.2024026781

Published: 2024

Includes: Supplemental data

Journal Articles

Less-deformable erythrocyte subpopulations biomechanically induce endothelial inflammation in sickle cell disease

Christina Caruso, Xiaopo Cheng, Marina E. Michaud, Hannah M. Szafraniec, Beena E. Thomas, Meredith E. Fay, Robert G. Mannino, Xiao Zhang, Yumiko Sakurai, Wei Li, David R. Myers, Clinton H. Joiner, David K. Wood, Manoj Bhasin, Michael D. Graham, Wilbur A. Lam

Blood (2024) 144 (19): 2050–2062.

https://doi.org/10.1182/blood.2024024608

Published: 2024

Includes: Supplemental data

Journal Articles

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

Jie Xiong, Shu Cheng, Hua-man Cai, Yu-Ran Qiu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2024-206718

Published: 2024

Journal Articles

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Yue Wang, Xue Wang, Xinyun Huang, Ying Qian, Rongji Mu, Qing Shi, Di Fu, Hongmei Yi, Bin-Shen Ou-Yang, Zhuo Han Li, Shu Cheng, Wang Li, Ning Wen, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2024-206537

Published: 2024

Journal Articles

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Jingwei Yu, Xiuhua Sun, Guangxun Gao, Li Yu, Jiesong Wang, Lihua Qiu, Zhengzi Qian, Wei Li, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6403.

https://doi.org/10.1182/blood-2024-204337

Published: 2024

Journal Articles

Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Ruirui Gui, Zhen Li, Juan Wang, Yingling Zu, Wenli Zhang, Xudong Li, Wei Li, Wenyi Lu, Chao Li, Xianjing Wang, Jian Zhou

Blood (2024) 144 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2024-204626

Published: 2024

Journal Articles

Combined Low-Dose TBI, Ivig, and DEX for Donor-Specific Antibody Desensitization in Haploidentical and Mmud Haematopoietic Stem Cell Transplantation： a Retrospective Multicenter Case-Control Study

Blood (2024) 144 (Supplement 1): 7104.

https://doi.org/10.1182/blood-2024-204549

Published: 2024

Journal Articles

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Tiantian Xie, Runqing Lu, Weijie Cao, Bian Zhilei, Wei Li, Zhongxing Jiang, Yongping Song, Dengju Li, Rong Guo

Blood (2024) 144 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2024-206974

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Yi-Lun Zhang, Lingshuang Sheng, Rong Shen, Wen Wu, Xin Zheng, Li Wang, Shu Cheng, Peng-Peng Xu, Qi-Jie Jian, Bo Peng, Ke Zhang, Fei Pang, Kai Wang, Zi-Xun Yan, Wei-Li Zhao

Blood (2024) 144 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2024-209889

Published: 2024

Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with Brentuximab Vedotin (BV)-Based Treatment Options in China

Hengge Xu, Wei Li, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6537.

https://doi.org/10.1182/blood-2024-207221

Published: 2024

Journal Articles

TET1 Drives Myelodysplastic Syndromes and Represents a Promising Therapeutic Target

Chao Shen, Tingting Tang, Kitty Wang, Zunsong Hu, Yuan Che, Meiling Chen, Keren Zhou, Zhenhua Chen, Ying Qing, Wei Li, Dong Wu, Keith Leung, Lillian Sau, Zhaoxu Xu, Lucy Y. Ghoda, Guido Marcucci, Xiaolan Deng, Jianjun Chen

Blood (2024) 144 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2024-199714

Published: 2024

Journal Articles

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Yuqing Wang, Shuo Wang, Hongmei Yi, Yue Wang, Haimin Xu, Shuang Tian, Yan Dong, Jing Zhao, Di Fu, Rongji Mu, Shuye Wang, Li Wang, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2024-202864

Published: 2024

Journal Articles

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Xudong Li, Hong Huang, Binglei Zhang, Zhongxing Jiang, Yongping Song, Wenyi Lu, Bian Zhilei, Wei Li, Weijie Cao

Blood (2024) 144 (Supplement 1): 6695.

https://doi.org/10.1182/blood-2024-201202

Published: 2024

Journal Articles

Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease

Wei Li, Andrew Pucka, Candice Debats, Brandon Reyes, Andrew Ross Wickman O'Brien, Steven E Harte, Richard E Harris, Qigui Yu, Ying Wang

Blood (2024) 144 (Supplement 1): 2519.

https://doi.org/10.1182/blood-2024-198474

Published: 2024

Journal Articles

Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Danielle C. Kirkey, Grace Hawkins, Melia Blankenfeld, Isabel Lira, Nika Panahi, Margaret G Hines, Seungmin Shin, Tiffany Hylkema, Cyd McKay, Christina Root, Logan K. Wallace, Jack H. Peplinski, Rhonda E. Ries, Concetta Quintarelli, Franco Locatelli, Wei Li, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 2050.

https://doi.org/10.1182/blood-2024-212075

Published: 2024

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2024-205438

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor

Chang-Tsu Yuan, Wei-Li Ma

Blood (2024) 143 (20): 2106.

https://doi.org/10.1182/blood.2024023818

Published: 2024

Journal Articles

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Biao Zheng, Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2023) 142 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2023-185573

Published: 2023

NARROW

Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation

Less-deformable erythrocyte subpopulations biomechanically induce endothelial inflammation in sickle cell disease

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Combined Low-Dose TBI, Ivig, and DEX for Donor-Specific Antibody Desensitization in Haploidentical and Mmud Haematopoietic Stem Cell Transplantation： a Retrospective Multicenter Case-Control Study

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with Brentuximab Vedotin (BV)-Based Treatment Options in China

TET1 Drives Myelodysplastic Syndromes and Represents a Promising Therapeutic Target

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease

Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only